001043580 001__ 1043580
001043580 005__ 20250804202237.0
001043580 0247_ $$2doi$$a10.1016/j.neurobiolaging.2025.06.006
001043580 0247_ $$2ISSN$$a0197-4580
001043580 0247_ $$2ISSN$$a1558-1497
001043580 0247_ $$2datacite_doi$$a10.34734/FZJ-2025-02937
001043580 0247_ $$2pmid$$a40582243
001043580 0247_ $$2WOS$$aWOS:001527114100001
001043580 037__ $$aFZJ-2025-02937
001043580 082__ $$a610
001043580 1001_ $$0P:(DE-HGF)0$$aAkradi, Mohammad$$b0
001043580 245__ $$aHow is self-reported sleep-disordered breathing linked with biomarkers of Alzheimer’s disease?
001043580 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2025
001043580 3367_ $$2DRIVER$$aarticle
001043580 3367_ $$2DataCite$$aOutput Types/Journal article
001043580 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1751447291_16639
001043580 3367_ $$2BibTeX$$aARTICLE
001043580 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001043580 3367_ $$00$$2EndNote$$aJournal Article
001043580 500__ $$aData collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12–2–0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.;Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.;Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Author SBE received Helmholtz Imaging Platform grant (NimRLS, ZT-I-PF-4–010). Author BM currently serves on a scientific advisory board for AstronauTx.
001043580 520__ $$aSleep-disordered breathing (SDB) is prevalent in Alzheimer’s disease (AD). Here, we assessed how self-reported SDB is linked with AD biomarkers, including amyloid-beta plaque burden (Aβ), regional fluorodeoxyglucose uptake (rFDG-PET), grey matter volume (GMV), cognitive scores, and cerebrospinal fluid (CSF) biomarkers. We selected 757 individuals, including AD, mild cognitive impairment (MCI), and cognitively unimpaired (CU) groups, and divided them according to self-reported SDB condition. Using a stratified subsampling approach, we selected 512 matched subsamples, and effect sizes (ES) of the group-SDB interaction were computed for each biomarker and cognitive score across subsamples. Linear regression assessed associations between the ES of Aβ, rFDG, and GMV with the ES of cognitive scores and CSF biomarkers. The group-SDB interaction had a medium-sized effect on Aβ, rFDG, and GMV biomarkers in several brain areas. Participants with SDB exhibited reduced Aβ burden and increased rFDG uptake in the CU and MCI groups, whereas the AD group showed elevated Aβ burden and decreased rFDG. Additionally, SDB+ individuals demonstrated GMV alterations across all groups. The ES of group-SDB interaction on Aβ in the precuneus, middle temporal gyrus, and fusiform gyrus was associated with the ES of cognitive scores. Taken together, we observed a robust association of SDB with Aβ pathology in PET and CSF relative to rFDG and GMV in the AD group, which was also associated with cognitive decline.
001043580 536__ $$0G:(DE-HGF)POF4-5251$$a5251 - Multilevel Brain Organization and Variability (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001043580 536__ $$0G:(DE-HGF)POF4-5252$$a5252 - Brain Dysfunction and Plasticity (POF4-525)$$cPOF4-525$$fPOF IV$$x1
001043580 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001043580 7001_ $$0P:(DE-HGF)0$$aFarzane-Daghigh, Tara$$b1
001043580 7001_ $$0P:(DE-HGF)0$$aEbneabbasi, Amir$$b2
001043580 7001_ $$0P:(DE-Juel1)190453$$aBi, Hanwen$$b3$$ufzj
001043580 7001_ $$0P:(DE-Juel1)177611$$aDrzezga, Alexander$$b4$$ufzj
001043580 7001_ $$0P:(DE-HGF)0$$aMander, Bryce A.$$b5
001043580 7001_ $$0P:(DE-Juel1)131678$$aEickhoff, Simon B.$$b6$$ufzj
001043580 7001_ $$0P:(DE-Juel1)188400$$aTahmasian, Masoud$$b7$$eCorresponding author
001043580 773__ $$0PERI:(DE-600)1498414-3$$a10.1016/j.neurobiolaging.2025.06.006$$gp. S0197458025001034$$p16-24$$tNeurobiology of aging$$v154$$x0197-4580$$y2025
001043580 8564_ $$uhttps://juser.fz-juelich.de/record/1043580/files/1-s2.0-S0197458025001034-main.pdf$$yOpenAccess
001043580 8767_ $$d2025-08-04$$eHybrid-OA$$jDEAL
001043580 909CO $$ooai:juser.fz-juelich.de:1043580$$pVDB$$pdriver$$pOpenAPC_DEAL$$popen_access$$popenaire$$popenCost$$pdnbdelivery
001043580 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)190453$$aForschungszentrum Jülich$$b3$$kFZJ
001043580 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177611$$aForschungszentrum Jülich$$b4$$kFZJ
001043580 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131678$$aForschungszentrum Jülich$$b6$$kFZJ
001043580 9101_ $$0I:(DE-HGF)0$$6P:(DE-Juel1)131678$$a HHU Düsseldorf$$b6
001043580 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)188400$$aForschungszentrum Jülich$$b7$$kFZJ
001043580 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5251$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001043580 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5252$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x1
001043580 9141_ $$y2025
001043580 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-13
001043580 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-13
001043580 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-13
001043580 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-13
001043580 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-13
001043580 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROBIOL AGING : 2022$$d2024-12-13
001043580 915__ $$0LIC:(DE-HGF)CCBYNC4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 4.0
001043580 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-13
001043580 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-13
001043580 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-13
001043580 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-13
001043580 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001043580 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-13
001043580 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-13
001043580 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-13$$wger
001043580 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-13
001043580 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
001043580 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
001043580 915pc $$0PC:(DE-HGF)0002$$2APC$$aDFG OA Publikationskosten
001043580 915pc $$0PC:(DE-HGF)0125$$2APC$$aDEAL: Elsevier 09/01/2023
001043580 9201_ $$0I:(DE-Juel1)INM-7-20090406$$kINM-7$$lGehirn & Verhalten$$x0
001043580 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x1
001043580 9801_ $$aFullTexts
001043580 980__ $$ajournal
001043580 980__ $$aVDB
001043580 980__ $$aUNRESTRICTED
001043580 980__ $$aI:(DE-Juel1)INM-7-20090406
001043580 980__ $$aI:(DE-Juel1)INM-2-20090406
001043580 980__ $$aAPC